RU2017141447A - Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 - Google Patents
Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 Download PDFInfo
- Publication number
- RU2017141447A RU2017141447A RU2017141447A RU2017141447A RU2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A RU 2017141447 A RU2017141447 A RU 2017141447A
- Authority
- RU
- Russia
- Prior art keywords
- influenza virus
- virus
- polypeptide
- vlp
- immune response
- Prior art date
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims 25
- 229920001184 polypeptide Polymers 0.000 title claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 13
- 239000000203 mixture Substances 0.000 title claims 8
- 230000028993 immune response Effects 0.000 title claims 7
- 238000000034 method Methods 0.000 title claims 7
- 206010069767 H1N1 influenza Diseases 0.000 title claims 6
- 201000010740 swine influenza Diseases 0.000 title claims 6
- 241000700605 Viruses Species 0.000 title 1
- 206010022000 influenza Diseases 0.000 title 1
- 101710154606 Hemagglutinin Proteins 0.000 claims 14
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 14
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 14
- 101710176177 Protein A56 Proteins 0.000 claims 14
- 239000000185 hemagglutinin Substances 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 102000005348 Neuraminidase Human genes 0.000 claims 4
- 108010006232 Neuraminidase Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 108060003393 Granulin Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (19)
1. Рекомбинантный полипептид гемагглютинина (HA) вируса гриппа для вызова иммунного ответа в отношении вируса гриппа H1N1, содержащий аминокислотную последовательность из остатков 2-566 SEQ ID NO: 2.
2. Полипептид HA вируса гриппа по п. 1, состоящий из аминокислотной последовательности из остатков 2-566 SEQ ID NO: 2.
3. Полипептид HA вируса гриппа по п. 1, содержащий аминокислотную последовательность SEQ ID NO: 2.
4. Полипептид HA вируса гриппа по п. 1, состоящий из аминокислотной последовательности SEQ ID NO: 2.
5. Выделенная молекула нуклеиновой кислоты, кодирующая полипептид HA вируса гриппа по любому из пп. 1-4.
6. Выделенная молекула нуклеиновой кислоты по п. 5, где молекула нуклеиновой кислоты подвергнута оптимизации кодонов для экспрессии в клетках млекопитающих.
7. Вектор экспрессии, содержащий молекулу нуклеиновой кислоты по п. 5 или 6.
8. Вектор по п. 7, дополнительно содержащий промотор, функционально связанный c последовательностью нуклеиновой кислоты, кодирующей полипептид HA вируса гриппа.
9. Выделенная клетка млекопитающего для продуцирования и экспрессии вирусоподобных частиц, сходных с частицами вируса гриппа H1N1 (VLP), содержащая вектор по п. 7 или 8.
10. Вирусоподобная частица, сходная с частицей вируса гриппа (VLP), для вызова иммунного ответа в отношении вируса H1N1, содержащая полипептид HA вируса гриппа по любому из пп. 1-4, белок нейраминидазу (NA) вируса гриппа и матриксный белок (M1) вируса гриппа.
11. VLP, сходная с частицей вируса гриппа, для вызова иммунного ответа в отношении вируса гриппа H1N1, содержащая полипептид HA вируса гриппа по любому из пп. 1-4, получаемая путем трансфекции клетки-хозяина млекопитающего с помощью вектора, кодирующего полипептид HA, вектора, кодирующего белок NA вируса гриппа, и вектора, кодирующего белок М1 вируса гриппа, в условиях, достаточных для обеспечения экспрессии белков HA, M1 и NA.
12. Слитый белок для вызова иммунного ответа в отношении вируса гриппа H1N1, содержащий полипептид HA вируса гриппа по любому из пп. 1-4, слитый с гетерологичным белком.
13. Композиция для вызова иммунного ответа в отношении вируса гриппа H1N1, содержащая терапевтически эффективное количество полипептида HA вируса гриппа по любому из пп. 1-4, VLP по п. 10 или 11 или слитого белка по п. 12 и фармацевтически приемлемый носитель.
14. Способ вызова иммунного ответа в отношении вируса гриппа у субъекта, включающий введение терапевтически эффективного количества полипептида HA вируса гриппа по любому из пп. 1-4, VLP по п. 10 или 11, слитого белка по п. 12 или композиции по п. 13.
15. Способ иммунизации субъекта против вируса гриппа, включающий введение субъекту композиции, содержащей терапевтически эффективное количество VLP по п. 10 или 11 и фармацевтически приемлемый носитель.
16. Способ по п. 15, где композиция дополнительно содержит адъювант.
17. Способ по п. 15 или 16, где композицию вводят внутримышечно.
18. Способ по любому из пп. 15-17, где композиция содержит от приблизительно 1 до приблизительно 25 мкг VLP.
19. Способ по п. 18, где композиция содержит приблизительно 15 мкг VLP.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617815P | 2012-03-30 | 2012-03-30 | |
| US61/617,815 | 2012-03-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014142785A Division RU2639551C2 (ru) | 2012-03-30 | 2013-03-12 | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017141447A true RU2017141447A (ru) | 2019-02-13 |
Family
ID=49261015
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017141447A RU2017141447A (ru) | 2012-03-30 | 2013-03-12 | Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 |
| RU2014142785A RU2639551C2 (ru) | 2012-03-30 | 2013-03-12 | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014142785A RU2639551C2 (ru) | 2012-03-30 | 2013-03-12 | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9212207B2 (ru) |
| EP (1) | EP2831094B1 (ru) |
| JP (1) | JP2015513902A (ru) |
| KR (1) | KR20150004800A (ru) |
| CN (1) | CN104395336B (ru) |
| AU (1) | AU2013240365B2 (ru) |
| BR (1) | BR112014023900A2 (ru) |
| CA (1) | CA2868330A1 (ru) |
| HK (1) | HK1203522A1 (ru) |
| IN (1) | IN2014DN07399A (ru) |
| MX (1) | MX345150B (ru) |
| MY (1) | MY166953A (ru) |
| RU (2) | RU2017141447A (ru) |
| SG (1) | SG11201406153XA (ru) |
| WO (1) | WO2013148164A1 (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2811103C (en) * | 2010-09-14 | 2020-01-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| CN106995488A (zh) | 2011-06-20 | 2017-08-01 | 高等教育联邦系统-匹兹堡大学 | 计算优化的宽反应性的h1n1流感抗原 |
| IN2015DN03070A (ru) * | 2012-11-27 | 2015-10-02 | Univ Pittsburgh | |
| US20140286981A1 (en) * | 2013-03-14 | 2014-09-25 | Wisconsin Alumni Research Foundation | Broadly reactive mosaic peptide for influenza vaccine |
| WO2016100922A1 (en) * | 2014-12-19 | 2016-06-23 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza |
| EP3233117A4 (en) * | 2014-12-19 | 2018-05-16 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| US10584148B2 (en) | 2015-06-02 | 2020-03-10 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| WO2016201127A1 (en) * | 2015-06-09 | 2016-12-15 | Sanofi Pasteur, Inc. | Methods of optimizing nucleotide sequences encoding engineered influenza proteins |
| US20200237898A1 (en) * | 2015-09-21 | 2020-07-30 | Oregon Health & Science University | Vaccines intelligently produced by epitope recombination (viper) for influenza |
| CA3026096A1 (en) * | 2016-06-02 | 2017-12-07 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| CN109563138B (zh) | 2016-06-03 | 2022-09-23 | 圣诺菲·帕斯图尔公司 | 经改造的流感血凝素多肽的修饰 |
| WO2019191257A1 (en) * | 2018-03-28 | 2019-10-03 | Sanofi Pasteur Inc. | Methods of generating broadly protective vaccine compositions comprising hemagglutinin |
| JP7329530B2 (ja) * | 2018-03-28 | 2023-08-18 | サノフィ パスツール インコーポレイテッド | ノイラミニダーゼを含む広範に防御的なワクチン組成物を生成する方法 |
| EP3773703A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic influenza-ferritin polypeptides |
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| EP3876983A4 (en) * | 2018-11-06 | 2022-08-03 | Boehringer Ingelheim Vetmedica GmbH | IMMUNOGENIC COMPOSITION AGAINST THE H5 SUBTYPE OF THE AVIAN INFLUENZA VIRUS |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE376059T1 (de) | 2000-06-23 | 2007-11-15 | Wyeth Corp | Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps) |
| US20050181459A1 (en) | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US7566454B2 (en) | 2005-02-24 | 2009-07-28 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| EP1909829A4 (en) | 2005-07-19 | 2009-11-11 | Dow Global Technologies Inc | RECOMBINANT GRIP VACCINES |
| CA2633793A1 (en) | 2005-12-19 | 2007-06-28 | Novartis Vaccines And Diagnostics S.R.L. | Methods of clustering gene and protein sequences |
| US20080045472A1 (en) | 2006-03-31 | 2008-02-21 | Council Of Scientific And Industrial Research Bharat Biotech | Targets for human micro rnas in avian influenza virus (h5n1) genome |
| MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| US8030029B2 (en) * | 2007-01-23 | 2011-10-04 | Academia Sinica | Flu vaccines and methods of use thereof |
| EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
| WO2009073330A2 (en) | 2007-11-12 | 2009-06-11 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
| SG187500A1 (en) | 2008-01-21 | 2013-02-28 | Medicago Inc | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin |
| US7981428B2 (en) | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
| WO2010036970A2 (en) | 2008-09-25 | 2010-04-01 | Fraunhofer Usa, Inc. | Influenza vaccines, antigens, compositions, and methods |
| WO2010036948A2 (en) * | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
| EP2414386B1 (en) | 2009-04-03 | 2016-01-27 | Merial Limited | Newcastle disease virus vectored avian vaccines |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| CA2811103C (en) | 2010-09-14 | 2020-01-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| CN106995488A (zh) | 2011-06-20 | 2017-08-01 | 高等教育联邦系统-匹兹堡大学 | 计算优化的宽反应性的h1n1流感抗原 |
| WO2013119683A1 (en) * | 2012-02-07 | 2013-08-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses |
| AU2013221877B2 (en) | 2012-02-13 | 2017-11-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for human and avian H5N1 influenza |
| IN2015DN03070A (ru) | 2012-11-27 | 2015-10-02 | Univ Pittsburgh |
-
2013
- 2013-03-12 EP EP13769077.2A patent/EP2831094B1/en active Active
- 2013-03-12 IN IN7399DEN2014 patent/IN2014DN07399A/en unknown
- 2013-03-12 RU RU2017141447A patent/RU2017141447A/ru not_active Application Discontinuation
- 2013-03-12 WO PCT/US2013/030530 patent/WO2013148164A1/en active Application Filing
- 2013-03-12 KR KR1020147027594A patent/KR20150004800A/ko not_active Application Discontinuation
- 2013-03-12 MX MX2014011387A patent/MX345150B/es active IP Right Grant
- 2013-03-12 RU RU2014142785A patent/RU2639551C2/ru not_active IP Right Cessation
- 2013-03-12 SG SG11201406153XA patent/SG11201406153XA/en unknown
- 2013-03-12 JP JP2015503258A patent/JP2015513902A/ja active Pending
- 2013-03-12 CN CN201380027311.0A patent/CN104395336B/zh not_active Expired - Fee Related
- 2013-03-12 AU AU2013240365A patent/AU2013240365B2/en not_active Ceased
- 2013-03-12 BR BR112014023900-2A patent/BR112014023900A2/pt not_active IP Right Cessation
- 2013-03-12 CA CA2868330A patent/CA2868330A1/en not_active Abandoned
- 2013-03-12 US US14/388,726 patent/US9212207B2/en active Active
- 2013-03-12 MY MYPI2014002785A patent/MY166953A/en unknown
-
2015
- 2015-04-24 HK HK15104016.5A patent/HK1203522A1/xx unknown
- 2015-11-12 US US14/939,279 patent/US9555095B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201406153XA (en) | 2014-10-30 |
| EP2831094B1 (en) | 2018-06-13 |
| US20160279226A1 (en) | 2016-09-29 |
| HK1203522A1 (en) | 2015-10-30 |
| US20150017196A1 (en) | 2015-01-15 |
| MX2014011387A (es) | 2014-10-14 |
| JP2015513902A (ja) | 2015-05-18 |
| WO2013148164A1 (en) | 2013-10-03 |
| IN2014DN07399A (ru) | 2015-04-24 |
| BR112014023900A2 (pt) | 2020-11-24 |
| KR20150004800A (ko) | 2015-01-13 |
| US9555095B2 (en) | 2017-01-31 |
| EP2831094A4 (en) | 2015-10-14 |
| RU2639551C2 (ru) | 2017-12-21 |
| MY166953A (en) | 2018-07-25 |
| CN104395336B (zh) | 2018-01-23 |
| AU2013240365B2 (en) | 2017-03-30 |
| MX345150B (es) | 2017-01-18 |
| CA2868330A1 (en) | 2013-10-03 |
| EP2831094A1 (en) | 2015-02-04 |
| US9212207B2 (en) | 2015-12-15 |
| RU2014142785A (ru) | 2016-05-20 |
| AU2013240365A1 (en) | 2014-10-23 |
| CN104395336A (zh) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017141447A (ru) | Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 | |
| RU2014101401A (ru) | Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств | |
| RU2018113521A (ru) | Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b | |
| JP6655623B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| JP2015506705A5 (ru) | ||
| JP6679475B2 (ja) | 安定化された可溶性融合前ｒｓｖ ｆポリペプチド | |
| RU2015124805A (ru) | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вируса гриппа h1n1 | |
| AU2021232702B2 (en) | Stabilized pre-fusion RSV F proteins | |
| EP3821906A1 (en) | Vaccine against rsv comprising modified f polypeptide | |
| TW201520221A (zh) | 穩定化可溶性融合前ｒｓｖ ｆ多肽 | |
| JP2016505538A5 (ru) | ||
| CN115850396A (zh) | 一种rsv纳米颗粒疫苗及其制备方法与应用 | |
| WO2017207477A1 (en) | Stabilized pre-fusion rsv f proteins | |
| JP2014519817A5 (ru) | ||
| US20160368949A1 (en) | Influenza virus recombinant proteins | |
| WO2013066365A1 (en) | Immunologic constructs and methods | |
| CA3213403A1 (en) | Modified chimeric coronavirus spike protein for enhancement of viral titers | |
| CN112707954A (zh) | 一种禽流感通用表位疫苗 | |
| CN109821014A (zh) | 一种多抗原仿生流感疫苗及其制备方法和应用 | |
| OA19273A (en) | Stabilized pre-fusion RSV F proteins. | |
| OA17539A (en) | Stabilized soluble prefusion RSV F polypeptides. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20201130 |